<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01576328</url>
  </required_header>
  <id_info>
    <org_study_id>MSB-DM003</org_study_id>
    <nct_id>NCT01576328</nct_id>
  </id_info>
  <brief_title>Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes</brief_title>
  <official_title>A Randomized, Placebo-Controlled Dose-Escalation Study to Assess the Safety and Tolerability of a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Type 2 Diabetes Sub-optimally Controlled on Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mesoblast, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mesoblast, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to assess the overall safety and tolerability of a single
      intravenous infusion of three doses of Mesenchymal Precursor Cells versus Placebo in subjects
      with Type 2 Diabetes inadequately controlled on Metformin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary objective of the study is to assess the safety and tolerability of MPC therapy</measure>
    <time_frame>116 Weeks</time_frame>
    <description>Outcomes include the measurement of the following safety parameters:
Adverse events and serious adverse events(including hypoglycemia)
Vital signs (BP, HR, RR, O2 saturation)
Physical examinations
Results of clinical laboratory tests (hematology, biochemistry, and urinalysis, flow cytometry Class I and Class II PRA % with specificity, antibovine and antimurine antibody analysis)
Pulmonary function test
Electrocardiograms
Chest X-ray
Fundus oculi examination</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MPC dose 1 or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MPC dose 2 or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MPC dose 3 or Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesenchymal Precursor Cells (MPCs)</intervention_name>
    <description>Single intravenous infusion of MPCs Dose 1</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesenchymal Precursor Cells (MPCs)</intervention_name>
    <description>Single intravenous infusion of MPCs Dose 2</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesenchymal Precursor Cells (MPCs)</intervention_name>
    <description>Single intravenous infusion of MPCs Dose 3</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Male and female subjects who are ≥ 18 and ≤ 80 years old

          -  Subjects diagnosed with type 2 diabetes at least one year prior to Screening and
             receiving a stable, therapeutic dose of metformin &gt; 1500 mg/day according to local
             prescribing information for at least 3 months prior to Screening or the highest
             tolerated dose &gt; 1000 mg/day documented in the subject's history

          -  HbA1c &gt; 7.0% and &lt; 10.5% at Screening

          -  C-peptide &gt; 0.8 ng/mL at Screening

          -  Body mass index (BMI) &gt; 22 and &lt; 45 kg/m2 at Screening

          -  Body weight &lt; 150 kg at Screening

        Key Exclusion Criteria:

          -  Prior participation in any stem cell study

          -  Women who are pregnant, intending to become pregnant during the study period or
             currently lactating

          -  History of active substance abuse (including alcohol) within the past 2 years. Current
             alcohol abuse is defined as daily consumption of &gt;3 alcoholic beverage. Current
             cigarette smoking &gt; 10 cigarettes per day

          -  Severe hypoglycemia (defined as requiring third party assistance) or repeated and/or
             frequent hypoglycemia episodes (&gt; 2 episodes/week) within one month prior to Screening

          -  Patients receiving treatment for type 2 diabetes with diet and exercise alone, insulin
             therapy within 6 months of Screening except if used transiently for &lt; 7 days for
             intercurrent illness or any other anti-diabetic medication except metformin within 3
             months of Screening

          -  Any concurrent medical condition/disorder or clinically symptomatic cardiovascular,
             gastrointestinal (including pancreatitis), renal, hematological, pulmonary, acute or
             chronic infectious disease, active retinal disease, or other disorder which in the
             Investigator's opinion would interfere with the subject's ability to complete the
             trial, would require administration of treatment that could affect the interpretation
             of the safety and efficacy variables or would preclude safe involvement in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>K Segal, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Mesoblast, Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SC Clinical Research</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Big Sky Clinical Research</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Endocrinology Clinical Research Center-Henderson</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance Against Diabetes/AAD Clinical Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Active Practices and Research</name>
      <address>
        <city>Newington</city>
        <state>New Hampshire</state>
        <zip>03801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Health Partners - Center for Clinical Reseach</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Diabetes and Endocrine Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Houston Clinical Research Services</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paragon Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wasatch Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research - Norfolk, Inc</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research - Richmond, Inc.</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Clinical Research Center</name>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <zip>98502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2012</study_first_submitted>
  <study_first_submitted_qc>April 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2012</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

